AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 38262066
Drug: Low-dose aspirin
RxNorm normalized name: low-dose aspirin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-dose aspirin (81 mg daily)
Trial: 33142495
Drug: Vitamin D3
RxNorm normalized name: Vitamin D3
DrugBank: Cholecalciferol (DB00169)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin D3 at 2,760 IU/kg plus 25OHD at 2,760 IU (69 μg)/kg
Trial: 35380078
Drug: Continuous siponimod
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous siponimod 2 mg/day
Trial: 34755994
Drug: 20 ml
RxNorm normalized name: Exact-Med, 20 mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 ml of normal saline 0.9% as irrigation solution (Group A)
Trial: 34755994
Drug: 40 ml
RxNorm normalized name: hydrogen peroxide 40 ML/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 ml of normal saline 0.9% as irrigation solution (Group B)
Trial: 34755994
Drug: 60 ml
RxNorm normalized name: Disposable Nurser 60 mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 60 ml of normal saline 0.9% as irrigation solution (Group C)
Trial: 32956446
Drug: 23-month ticagrelor
RxNorm normalized name: Ticagrelor
DrugBank: Ticagrelor (DB08816)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 23-month ticagrelor monotherapy following 1-month dual anti-platelet therapy (DAPT)
Trial: 32956446
Drug: 23-month ticagrelor
RxNorm normalized name: Ticagrelor
DrugBank: Ticagrelor (DB08816)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 23-month ticagrelor monotherapy following 1-month DAPT
Trial: 35527411
Drug: Adaptive biofeedback
RxNorm normalized name: ADAPT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adaptive biofeedback training combined with oral administration of compound polyethylene glycol 4000-electrolyte powder
Trial: 35527411
Drug: Oral administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral administration of compound polyethylene glycol 4000-electrolyte powder alone
Trial: 34517840
Drug: Dexmedetomidine (1.25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexmedetomidine (1.25 µg/mL)
Trial: 35342437
Drug: Olibanum extract
RxNorm normalized name: Origanum majorana extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Olibanum extract orally disintegrating tablets (ODT), 4 times a day for 3 days
Trial: 35342437
Drug: Placebo orally
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo orally disintegrating tablets (ODT), 4 times a day for 3 days
Trial: 33208831
Drug: morphine (0.08
FDA approved: no
EMA approved: no
PMDA approved: no
Description: morphine (0.08 mg/kg) after forced awakening (FA)
Trial: 33208831
Drug: morphine after
FDA approved: no
EMA approved: no
PMDA approved: no
Description: morphine after forced awakening (FA) in females
Trial: 35012992
Drug: Superficial cervical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Superficial cervical plexus block (20 mL of 0.5% ropivacaine)
Trial: 35531757
Drug: Tramadol (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tramadol (2 mg/kg)
Trial: 32569281
Drug: Iron intake
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Iron intake less than 180 tablets
Trial: 32034028
Drug: Luseogliflozin 2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Luseogliflozin 2.5 mg once daily for 8 weeks
Trial: 36404985
Drug: Chewing gum
RxNorm normalized name: Chewing Gum
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chewing gum in addition to standard therapy
Trial: 36404985
Drug: Standard therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard therapy (Ondansetron 4 mg IV intra-operatively)
Trial: 32359936
Drug: Nanoemulsion eye
RxNorm normalized name: ANA-conjugated dactinomycin nanoemulsion
DrugBank: Dactinomycin (DB00970)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nanoemulsion eye drop (used for 1 month, four times daily)
Trial: 32078353
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of inreach and outreach
Trial: 32343960
Drug: JNJ-6379 (25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: JNJ-6379 (25 mg, 75 mg, 150 mg, or 250 mg daily for 4 weeks)
Trial: 32343960
Drug: JNJ-6379 (any
FDA approved: no
EMA approved: no
PMDA approved: no
Description: JNJ-6379 (any dose)
Trial: 32343960
Drug: JNJ-6379 (150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: JNJ-6379 (150 mg)
Trial: 35263680
Drug: 40 mg/day
RxNorm normalized name: cabozantinib s-malate 140 mg/day (80 mg x 1-20 mg x 3/day) ORAL CAPSULE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 mg/day ifenprodil tartrate for 4 weeks
Trial: 33298117
Drug: Daily use
RxNorm normalized name: ALCOHOL 75 mL in 100 mL TOPICAL GEL [Better For Daily Use EAAE Disinfectant]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily use of the Insight Timer meditation app for 10 minutes daily for 30 days
Trial: 35121137
Drug: Two additional
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two additional intensive oral hygiene appointments before and after GA
Trial: 36199780
Drug: Hormone group
RxNorm normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hormone group (prednisone acetate, n = 34)
Trial: 36199780
Drug: Combination group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination group (Ginkgo‐Damole combined with prednisone acetate, n = 30)
Trial: 38326432
Drug: Diphenhydramine (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diphenhydramine (50 mg)
Trial: 32311398
Drug: PF-06700841 100
RxNorm normalized name: PF-06700841
DrugBank: PF-06700841 (DB15003)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PF-06700841 100 mg once weekly
Trial: 37844838
Drug: Oral glucose
RxNorm normalized name: glucose Oral Gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral glucose administration
Trial: 37844838
Drug: Intravenous glucose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous glucose administration
Trial: 35852274
Drug: 20-mL buffered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20-mL buffered 1% lidocaine paracervical block
Trial: 35852274
Drug: 40-mL buffered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40-mL buffered 0.5% lidocaine paracervical block
Trial: 35852274
Drug: 40-mL buffered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40-mL buffered 0.5% lidocaine paracervical block (induced abortion)
Trial: 35852274
Drug: 20-mL buffered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20-mL buffered 1% lidocaine paracervical block (induced abortion)
Trial: 35852274
Drug: 20-mL buffered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20-mL buffered 1% lidocaine paracervical block (pain during administration)
Trial: 35852274
Drug: 40-mL buffered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40-mL buffered 0.5% lidocaine paracervical block (pain during administration)
Trial: 33081705
Drug: Medication placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medication placebo
Trial: 35803368
Drug: Target-Controlled Infusion
RxNorm normalized name: Diphtheria toxin-il-3 fusion protein targeting IL-3 receptor
DrugBank: Tagraxofusp (DB14731)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Target-Controlled Infusion (TCI) of propofol (effect-site, 2 μg.mL−1 plus 0.5 μg.mL−1 until unconsciousness and as necessary for agitation)
Trial: 35803368
Drug: Intermittent bolus
RxNorm normalized name: Peumus boldus leaf extract
DrugBank: Boldo leaf extract (DB15815)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intermittent bolus of propofol (1 mg.kg−1 plus 0.5 mg.kg−1 every 5 minutes or as necessary)
Trial: 32900329
Drug: Acetylsalicylic acid
RxNorm normalized name: ACETYLSALICYLIC ACID
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Acetylsalicylic acid (ASA) 100 mg 12-hourly
Trial: 32731829
Drug: Incisional negative-pressure
RxNorm normalized name: DRESSING,NEGATIVE PRESSURE WOUND
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Incisional negative-pressure wound therapy (iNPWT)
Trial: 32331049
Drug: 1800 mg
RxNorm normalized name: glycerin 1800 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1800 mg SPN-812 (supratherapeutic dose)
Trial: 35000914
Drug: HEP+CWHi (Constant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HEP+CWHi (Constant Ultrasound, 10% hydrocortisone gel, 10 minutes, 1.0 MHz, 100% duty cycle, 1.0 W/cm2)
Trial: 35000914
Drug: HEP+PWLi (Low
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HEP+PWLi (Low Intensity Ultrasound, 10% hydrocortisone gel, 10 minutes, 1.0 MHz, 50% duty cycle, 0.5 W/cm2)
Trial: 35000914
Drug: HEP+CWLi (Low
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HEP+CWLi (Low Intensity Ultrasound, 10% hydrocortisone gel, 10 minutes, 1.0 MHz, 100% duty cycle, 0.5 W/cm2)
Trial: 32522156
Drug: LOR (group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LOR (group L)
Trial: 36117007
Drug: Arthrocentesis as
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Arthrocentesis as initial treatment
Trial: 33632925
Drug: Nivolumab with
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nivolumab with ipilimumab and two cycles of platinum-doublet chemotherapy
Trial: 32223044
Drug: High dose
RxNorm normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High dose EPC (140 mg EPC and 130 mg OPC)
Trial: 32223044
Drug: OPC (6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: OPC (6 mg EPC and 130 mg OPC)
Trial: 32950416
Drug: Litos drug-coated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Litos drug-coated balloon (DCB)
Trial: 34263700
Drug: Infliximab added
RxNorm normalized name: Infliximab
DrugBank: Infliximab (DB00065)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Infliximab added to DMARD combination
Trial: 34263700
Drug: Placebo added
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo added to DMARD combination
Trial: 33469270
Drug: Reference drug
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reference drug (OcalivaTM) under fasting conditions
Trial: 33469270
Drug: Reference drug
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reference drug (OcalivaTM) under fed conditions
Trial: 33469270
Drug: Food intake
RxNorm normalized name: ALLERGENIC EXTRACT, FOOD, WHEAT
DrugBank: Wheat (DB10579)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Food intake effect on pharmacokinetics
Trial: 34325772
Drug: Tinidazole 200
RxNorm normalized name: tinidazole 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tinidazole 200 mg/kg PO (single dose)
Trial: 32076124
Drug: Symptomatic treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Symptomatic treatment
Trial: 32347785
Drug: Licensed trivalent
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Licensed trivalent influenza vaccines (TIVs)
Trial: 32928709
Drug: Alirocumab 300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alirocumab 300 mg Q4W
Trial: 34037351
Drug: Ethylmethylhydroxypyridine succinate
RxNorm normalized name: succinate
DrugBank: Emoxypine (DB19172)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ethylmethylhydroxypyridine succinate (Neurox) 1 tablet (125 mg) 3 times a day for 4 weeks
Trial: 35037963
Drug: BCG (once
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BCG (once weekly for 6 weeks plus subsequent maintenance)
Trial: 33726834
Drug: GSK2982772 60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GSK2982772 60 mg orally 2 or 3 times daily for 84 days
Trial: 33726834
Drug: GSK2982772 60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GSK2982772 60 mg
Trial: 37169401
Drug: CPAP treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CPAP treatment for 4 weeks
Trial: 35696054
Drug: RIV‐TDS Test
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RIV‐TDS Test Product (transdermal patch formulation of Rivastigmine with a release rate of 13.3 mg/24 h)
Trial: 35696054
Drug: Exelon Marketed
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Exelon Marketed Reference Product (transdermal patch formulation of Rivastigmine with a release rate of 13.3 mg/24 h)
Trial: 32926604
Drug: Dasotraline (4,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dasotraline (4, 6, or 8 mg/d)
Trial: 35485182
Drug: Test product
RxNorm normalized name: Patch test product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Test product (Haizheng Pharmaceutical Group)
Trial: 35485182
Drug: Reference drug
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reference drug (AstraZeneca Pharmaceuticals LP)
Trial: 36271849
Drug: RCF 75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RCF 75 mg once daily (QD)
Trial: 36271849
Drug: RCF (both
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RCF (both doses)
Trial: 35613823
Drug: Standard care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard care (pain control with analgesics, physical therapy, and osteoporosis medication)
Trial: 33467951
Drug: Mouthwashes (teas,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mouthwashes (teas, supplements, oil applications)
Trial: 33637332
Drug: Tegoprazan (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tegoprazan (100 mg/d) with triple-antibiotic therapy (1500 mg/d metronidazole, 2000 mg/d tetracycline, and 1200 mg/d bismuth) for 7 days
Trial: 33637332
Drug: Triple-antibiotic therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triple-antibiotic therapy (1500 mg/d metronidazole, 2000 mg/d tetracycline, and 1200 mg/d bismuth) with tegoprazan for 7 days
Trial: 32639369
Drug: Placebo group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo group (informed it may be a local anaesthetic cream)
Trial: 32639369
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (informed the cream was inactive)
Trial: 33004536
Drug: Abituzumab 1500
RxNorm normalized name: sacituzumab
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Abituzumab 1500 mg
Trial: 33004536
Drug: Abituzumab 500
RxNorm normalized name: sacituzumab
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Abituzumab 500 mg
Trial: 39104653
Drug: Abrocitinib 100
RxNorm normalized name: abrocitinib 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Abrocitinib 100 mg
Trial: 32340820
Drug: Ketamine (4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketamine (4 mg/kg IM or 1 mg/kg IV)
Trial: 32340820
Drug: Haloperidol (5-10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Haloperidol (5-10 mg IM or IV) + Lorazepam (1-2 mg IM or IV)
Trial: 36323602
Drug: Sublingual melatonin
RxNorm normalized name: Melatonin/Pyridoxine 2.5 MG-0.338 MG Sublingual Tablet [BASIC'S SUBLINGUAL MELATONIN WITH B6]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sublingual melatonin 3 mg
Trial: 36281107
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group with no treatment
Trial: 33612485
Drug: Epinephrine plus
RxNorm normalized name: Epinephrine
DrugBank: Epinephrine (DB00668)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Epinephrine plus vasopressin (0.1 mL per kg vasopressin, 0.1 mL per kg epinephrine 1:10000)
Trial: 35837022
Drug: Phenylephrine 70,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Phenylephrine 70, 80, 90, 100, and 110 μg for normotension
Trial: 35346389
Drug: Kinesiology tape,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Kinesiology tape, elevation and massage (Trial Treatment - TT)
Trial: 35346389
Drug: Treatment as
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment as usual (compression, elevation and massage - TAU)
Trial: 37985968
Drug: eptinezumab 300
RxNorm normalized name: Eptinezumab
DrugBank: Eptinezumab (DB14040)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: eptinezumab 300 mg
Trial: 34551130
Drug: eptinezumab (both
FDA approved: no
EMA approved: no
PMDA approved: no
Description: eptinezumab (both doses)
Trial: 33035700
Drug: IND/GLY/MF 150/50/160
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IND/GLY/MF 150/50/160 μg
Trial: 34009141
Drug: Bicarbonate treatment
RxNorm normalized name: Potassium Bicarbonate
DrugBank: Potassium bicarbonate (DB11098)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bicarbonate treatment
Trial: 32903368
Drug: Psychological therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Psychological therapy
Trial: 32568096
Drug: Rosuvastatin (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rosuvastatin (40 mg loading dose)
Trial: 35224090
Drug: Conventional physical
RxNorm normalized name: hypochlorite
DrugBank: Hypochlorite (DB11123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional physical therapy alone (non-CPM group)
Trial: 35618629
Drug: Platinum-doublet chemotherapy
RxNorm normalized name: platinum
DrugBank: Platinum (DB12257)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Platinum-doublet chemotherapy plus radiotherapy with pembrolizumab plus olaparib (Group B)
Trial: 35618629
Drug: Durvalumab monotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Durvalumab monotherapy (Group C)
Trial: 36763359
Drug: Sham laser
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sham laser therapy (SLT)
Trial: 35264432
Drug: Baricitinib 4
RxNorm normalized name: baricitinib 4 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Baricitinib 4 mg or Baricitinib 4 mg + MTX
Trial: 33638221
Drug: Oral vancomycin
RxNorm normalized name: Vancomycin
DrugBank: Vancomycin (DB00512)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral vancomycin (OVT)
Trial: 33424089
Drug: Group A:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group A: 1gr/8hours IV acetaminophen and 50mg/6hours IM pethidine
Trial: 33424089
Drug: Group B:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group B: 1gr/8hours IV acetaminophen and 40mg/12hours IV parecoxib
Trial: 33424089
Drug: Group C:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group C: 1gr/8hours IV acetaminophen monotherapy
Trial: 33940389
Drug: Soticlestat (up
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Soticlestat (up to 300 mg BID)
Trial: 32542873
Drug: Selective serotonin
RxNorm normalized name: Selective serotonin (5HT1) agonists
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Selective serotonin reuptake inhibitors
Trial: 34634436
Drug: Dose-escalated chemoradiation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dose-escalated chemoradiation (5 × 3 gray boost + CRT)
Trial: 34050531
Drug: Delayed delivery
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Delayed delivery of an oral health intervention
Trial: 33181560
Drug: Conventional oxygen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional oxygen therapy (Control)
Trial: 33231489
Drug: AMG 301
RxNorm normalized name: AMG 108
DrugBank: AMG 108 (DB05545)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AMG 301 420 mg every 2 weeks
Trial: 35940353
Drug: Oxycodone group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oxycodone group (10 mg extended-release oxycodone hydrochloride)
Trial: 34256830
Drug: Telerehabilitation (smartphone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Telerehabilitation (smartphone app with personalized program of resistance, balance, and daily activity training exercises)
Trial: 35810307
Drug: Aspirin 75
RxNorm normalized name: aspirin 75 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin 75 mg (Group B)
Trial: 35810307
Drug: Atorvastatin vs
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atorvastatin vs Control (Group D)
Trial: 35810307
Drug: Aspirin vs
RxNorm normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Aspirin vs Control (Group D)
Trial: 35810307
Drug: Both Atorvastatin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both Atorvastatin and Aspirin (Group C)
Trial: 33865929
Drug: PCIT-ED treatment
RxNorm normalized name: Ed-APAP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PCIT-ED treatment (n = 64)
Trial: 34098039
Drug: Pill counts
RxNorm normalized name: oteseconazole
DrugBank: Oteseconazole (DB13055)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pill counts adherence at 3 weeks
Trial: 34098039
Drug: Pill counts
RxNorm normalized name: oteseconazole
DrugBank: Oteseconazole (DB13055)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pill counts adherence at 7 weeks
Trial: 34098039
Drug: Agreement between
RxNorm normalized name: CYCLIZED P12 (PEPTIDE BOND BETWEEN THE CARBOXY AND AMINO-TERMINAL ENDS OF THE LINEAR PEPTIDE PSHISKYILRWRPK)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Agreement between self-report and pill counts at 3 weeks
Trial: 34957959
Drug: Unimanual mirror
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Unimanual mirror therapy (UMT)
Trial: 34957959
Drug: Bimanual mirror
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Bimanual mirror therapy (BMT)
Trial: 36174744
Drug: Placebo (0.9%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (0.9% saline solution)
Trial: 33611380
Drug: Internet-based cognitive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Internet-based cognitive behavioural therapy
Trial: 33216613
Drug: TRK (Thor-Ra-Nee-San-Tha-Kat)
RxNorm normalized name: TRK-250
DrugBank: TRK-250 (DB18500)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TRK (Thor-Ra-Nee-San-Tha-Kat) - 500 mg capsules, 2 capsules once daily before bed for 14 days
Trial: 33216613
Drug: Naproxen -
RxNorm normalized name: Naproxen
DrugBank: Naproxen (DB00788)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Naproxen - 250 mg tablets, 2 tablets twice a day after meals for 14 days
Trial: 32756176
Drug: Yangxinshi (YXS)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Yangxinshi (YXS) tablet
Trial: 32424430
Drug: Continuation of
RxNorm normalized name: varenicline
DrugBank: Varenicline (DB01273)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Continuation of PD-1 pathway inhibitors